Aligos Therapeutics, Inc. (ALGS) – What Are Investment Firms Saying About This Stock?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $38.50.

Several equities analysts have weighed in on ALGS shares. Jefferies Financial Group started coverage on shares of Aligos Therapeutics in a research report on Monday. They set a “strong-buy” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Finally, Weiss Ratings downgraded Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALGS. Bank of America Corp DE increased its stake in Aligos Therapeutics by 1,652.8% in the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after buying an additional 216,646 shares during the period. SummitTX Capital L.P. boosted its stake in shares of Aligos Therapeutics by 6.7% during the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Aligos Therapeutics by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the period. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Trading Down 8.3%

Shares of ALGS opened at $1.98 on Friday. Aligos Therapeutics has a one year low of $1.92 and a one year high of $13.69. The company has a 50-day moving average of $5.02 and a two-hundred day moving average of $6.06.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Friday, November 6th. The company reported ($2.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.19. The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $4.85 million. Aligos Therapeutics had a negative net margin of 197.01% and a negative return on equity of 206.30%. Equities analysts forecast that Aligos Therapeutics will post -6.61 EPS for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections. Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.